MODIFICATION TO DEVELOPMENT AND MARKETING AGREEMENT
THIS
MODIFICATIONAGREEMENT dated July 21, 2008 applies to the DEVELOPMENT AND
MARKETING AGREEMENT (the "Agreement') made and entered into and effective as
of
December 15, 2003 by and between BioCheck, Inc., a California corporation
('BioCheck") and AngioGenex, Inc., a New York corporation
("Angio').
Modification
Pursuant
to Section 14 (H) of the Agreement, the Parties agree to modify the Agreement
to
remove Section 3 (C) entitled "Minimum Annual Licensing Fee.” As a result of
this modification BioCheck shall have no past, current, or future contractual
obligation to pay Angio any minimum annual royalties called for under Section
3
( C) of the Agreement.
IN
WITNESS WHERE OF, duly authorized representatives of each of the Parties has
executed and delivered this Modification Agreement as of the Effective
Date.
|
BIOCHECK,
INC.
|
ANGIOGENEX
, INC.
|
||||
|
By:
|
By:
|
||||
|
Dr.
Xxxx Xxxx, President
|
Xxxx
Xxxxxxx, Chief Operating Officer
|
||||
